Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds
April 23 (UPI) -- Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.
Lilly is suing Mochi Health, Henry Meds, Willow Health and Fella Health, claiming they are illegally selling compounded versions of tirzepatide.
Lilly's suits argue that the knock-off tirzepatide compounds are not really personalized since they are mass-produced and prescribed to many patients.
Tirzepatide is the active ingredient in Lilly weight-loss drug Zepbound and the diabetes drug Mounjaro.
The suits claim the companies are allegedly deceiving customers and turning consumers away from the Lilly-branded medicines.
The compounding of Mounjaro happened in 2022 when a shortage of the drug allowed pharmacies and other facilities to produce compounds of the pharmaceutical.
Lilly brought in $16.4 billion in revenue last year from Zepbound and Mounjaro.
The sued companies did not immediately respond directly to the lawsuits, but Mochi Health told Wired in a general statement that compounded medications are customized by Mochi for "medical necessity."
"Their use remains appropriate and legal when tailored to individual patient needs and prescribed by a licensed medical provider-not as mass-market substitutes for branded medications," Mochi's statement said.
Mochi Health CEO Myra Ahmad told CNBC in March it planned to keep selling compounded versions of tirzepatide.
Lilly's suits against the telehealth companies seeks to prevent them from selling or marketing their versions of tirzepatide.
Lilly alleged the companies are mass-marketing slightly different versions of Lilly drugs to get around Food and Drug Administration rules.
The suits filed Wednesday are the latest in an ongoing battle Lilly is waging against the compounding of its pharmaceuticals.
In a September 2023 statement referencing its lawsuits against compounders, Lilly said it "filed this lawsuit to protect patients.
"Lilly cannot validate the safety or effectiveness of products claiming to contain tirzepatide that are not our own branded product," it said.
Before Wednesday's lawsuits, Lilly had sued over a dozen pharmacies, medical spas and wellness centers for selling compounds of tirzepatide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
Mochi Health Launches Enhanced Online Platform to Support Medical Weight Loss Patients Nationwide
SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) — Mochi Health, a physician-founded telehealth company delivering medical weight loss care directly to patients, announced today the launch of its newly upgraded online platform. The improvements are designed to streamline patient onboarding, optimize communication with healthcare providers, and expand access to evidence-based obesity care across the United States. As public interest in medical weight management continues to surge, Mochi Health is responding with scalable, user-centric technology that supports safe and affordable access to GLP-1 medications, personalized nutrition counseling, and long-term metabolic health tracking. 'We've redesigned the platform to make science-backed care easier to access, especially for patients who've historically been underserved,' said a Mochi Health spokesperson. 'This update reflects our commitment to clinical quality and digital innovation.' Key Platform Enhancements Include: Faster Onboarding Process: Patients can now begin care in as little as 24 hours after sign-up through an improved eligibility screening interface. Patients can now begin care in as little as 24 hours after sign-up through an improved eligibility screening interface. Telehealth Optimization: Real-time chat and video appointment scheduling enhance the provider-patient experience. Real-time chat and video appointment scheduling enhance the provider-patient experience. Medication Monitoring: Seamless tracking of GLP-1 prescriptions such as semaglutide and tirzepatide, with built-in refill reminders and dosage review tools. Seamless tracking of GLP-1 prescriptions such as semaglutide and tirzepatide, with built-in refill reminders and dosage review tools. Insurance Navigation Support: Enhanced tools help patients check coverage eligibility and minimize out-of-pocket costs. Supporting a Growing Public Health Need Obesity affects more than 42% of adults in the U.S., yet millions still lack access to affordable, comprehensive care. Mochi Health bridges this gap through board-certified obesity medicine specialists, a fully digital care model, and a mission to make evidence-based treatment options—including weight-loss medications—more accessible. With this latest platform release, Mochi Health aims to scale its outreach and ensure patients in all 50 states can take control of their health journey from the comfort of their homes. About Mochi Health Mochi Health is a physician-led digital health company providing individualized weight loss programs through telemedicine. The company offers GLP-1 prescriptions (where appropriate), lifestyle coaching, and medical supervision tailored to each patient's biology and health history. Headquartered in San Francisco, California, Mochi Health is redefining obesity care with compassion, science, and accessibility. For more information, visit Contact:Mochi Health Email: [email protected] Phone: +1 (619) 648-1247 Website:
Miami Herald
4 hours ago
- Miami Herald
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. Don't miss the move: Subscribe to TheStreet's free daily newsletter As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk (NVO) , while Eli Lilly (LLY) makes Zepbound and Mounjaro. Image source:One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's (MCD) and Domino's Pizza (DPZ) . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 yearsMajor restaurant chain quietly closes several locationsIconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. "But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market," said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients. Related: McDonald's analyst grills new stock price target on McCrispy reaction "Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $455.49. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
5 hours ago
- Yahoo
Mochi Health Launches Enhanced Online Platform to Support Medical Weight Loss Patients Nationwide
Updated Virtual Weight Loss Platform Expands Access to GLP-1 Support and Clinician-Guided Obesity Care Across All 50 States SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) -- Mochi Health, a physician-founded telehealth company delivering medical weight loss care directly to patients, announced today the launch of its newly upgraded online platform. The improvements are designed to streamline patient onboarding, optimize communication with healthcare providers, and expand access to evidence-based obesity care across the United States. As public interest in medical weight management continues to surge, Mochi Health is responding with scalable, user-centric technology that supports safe and affordable access to GLP-1 medications, personalized nutrition counseling, and long-term metabolic health tracking. 'We've redesigned the platform to make science-backed care easier to access, especially for patients who've historically been underserved,' said a Mochi Health spokesperson. 'This update reflects our commitment to clinical quality and digital innovation.' Key Platform Enhancements Include: Faster Onboarding Process: Patients can now begin care in as little as 24 hours after sign-up through an improved eligibility screening interface. Telehealth Optimization: Real-time chat and video appointment scheduling enhance the provider-patient experience. Medication Monitoring: Seamless tracking of GLP-1 prescriptions such as semaglutide and tirzepatide, with built-in refill reminders and dosage review tools. Insurance Navigation Support: Enhanced tools help patients check coverage eligibility and minimize out-of-pocket costs. Supporting a Growing Public Health Need Obesity affects more than 42% of adults in the U.S., yet millions still lack access to affordable, comprehensive care. Mochi Health bridges this gap through board-certified obesity medicine specialists, a fully digital care model, and a mission to make evidence-based treatment options—including weight-loss medications—more accessible. With this latest platform release, Mochi Health aims to scale its outreach and ensure patients in all 50 states can take control of their health journey from the comfort of their homes. About Mochi Health Mochi Health is a physician-led digital health company providing individualized weight loss programs through telemedicine. The company offers GLP-1 prescriptions (where appropriate), lifestyle coaching, and medical supervision tailored to each patient's biology and health history. Headquartered in San Francisco, California, Mochi Health is redefining obesity care with compassion, science, and accessibility. For more information, visit Contact:Mochi HealthEmail: hello@ +1 (619) 648-1247Website: SOURCE: Mochi Health Disclaimer: This press release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individuals should consult with a licensed healthcare provider before beginning any medical weight loss program or treatment. Results may vary. The services described herein are subject to applicable laws and medical oversight. Mochi Health does not guarantee specific outcomes and makes no warranties regarding the effectiveness of any particular treatment plan. CONTACT: Email: hello@ Phone: +1 (619) 648-1247Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
